NDA 022483 · Bausch
Zyclara
Imiquimod · Topical
Last checked: Nov 20, 2026Latest source record: Sep 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Mar 25, 2010
Approved uses
3
Original approval plus efficacy supplements
Registered trials
185
42 Phase 3, 12 recruiting
FAERS reports
2,334
1,287 serious, 73 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 30, 2025.
Imiquimod Cream, 3.75% is indicated for the topical treatment of clinically typical, visible, or palpable actinic keratoses (AK) of the face or balding scalp in immunocompetent adults. ( 1.1 ) Imiquimod Cream, 3.75% is indicated for the topical treatment of external genital and perianal warts (EGW) in immunocompetent patients 12 years of age or older. ( 1.2 ) 1.1 Actinic Keratosis Imiquimod Cream, 3.75% is indicated for the topical treatment of clinically typical, visible or palpable actinic keratoses (AK) of the face or balding scalp in immunocompetent adults. 1.2 External Genital Warts Imiquimod Cream, 3.75% is indicated for the topical treatment of external genital and perianal warts (EGW) in immunocompetent patients 12 years of age and older.
Mechanism: The mechanism of action of Imiquimod Cream in the treatment of AK and EGW is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 15, 2011 Supplement 3 · Efficacy LetterLabel
- Mar 24, 2011 Supplement 1 · Efficacy LetterLabel
- Mar 25, 2010 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
2 products under this application
- ZYCLARA · IMIQUIMOD 3.75% · CREAM, TOPICAL · Prescription · TE AB
- ZYCLARA · IMIQUIMOD 2.5% · CREAM, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Imiquimod" as an intervention, any sponsor and status, largest first.
- Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade LesionsPivotal-lookingCompleted
AIDS Malignancy ConsortiumResearch network
NCT02135419 · 4,446 participants · Start Sep 24, 2014 · Primary completion Aug 6, 2021
Drug: imiquimod; fluorouracil · For: Anal Cancer; High-grade Squamous Intraepithelial Lesion; HIV Infection and 1 more
Sites: Los Angeles, California; Palm Springs, California; San Francisco, California · 25 sites in all
- Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness PatientsPivotal-lookingStatus unknown
The University of Hong KongAcademic, hospital or other
NCT04143451 · 4,000 participants (planned) · Start Oct 23, 2019 · Primary completion Sep 30, 2022
Drug: Vaxigrip tetra; Fluzone high-dose and 2 more · For: Influenza
Sites: Hong Kong, Hong Kong
- Basal Cell Carcinoma Chemoprevention TrialPivotal-lookingRecruiting
VA Office of Research and DevelopmentFederal agency
NCT05212246 · 1,630 participants (planned) · Start Oct 6, 2026 · Primary completion Oct 6, 2032
Drug: 5% Imiquimod cream; Placebo Vehicle Control Cream · For: Basal Cell Carcinoma
Sites: Long Beach, California; San Diego, California; Bay Pines, Florida · 8 sites in all
- IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic KeratosisPivotal-lookingStatus unknown
Maastricht University Medical CenterAcademic, hospital or other
NCT02281682 · 624 participants · Start Nov 2014 · Primary completion Jul 2018
Drug: Imiquimod; 5-fluorouracil and 1 more · For: Keratosis, Actinic
Sites: Maastricht, Netherlands
- Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic KeratosisPivotal-lookingCompleted
Teva Pharmaceuticals USATeva (TEVA)
NCT01686152 · 589 participants · Start Sep 2012 · Primary completion Aug 2013
Drug: Imiquimod Cream, 3.75%; Zyclara® · For: Actinic Keratosis
Sites: Tucson, Arizona; Encino, California; Los Angeles, California · 23 sites in all
- Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic KeratosisCompleted
Graceway Pharmaceuticals, LLCIndustry
NCT00116649 · 551 participants · Start Jun 2005 · Primary completion May 2007
Drug: imiquimod cream · For: Keratosis
Sites: Phoenix, Arizona; Encino, California; Los Angeles, California · 32 sites in all
- Phase 3 Study of Imiquimod Creams in the Treatment of External Genital WartsPivotal-lookingCompleted
Graceway Pharmaceuticals, LLCIndustry
NCT00735462 · 511 participants · Start Aug 2008 · Primary completion Jul 2009
Drug: 2.5% imiquimod cream; 3.75% imiquimod cream and 1 more · For: Genital Warts
Sites: Jonesboro, Arkansas; Carmichael, California; Chico, California · 43 sites in all
- Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSILPivotal-lookingRecruiting
Erasmus Medical CenterAcademic, hospital or other
NCT06052696 · 500 participants (planned) · Start Mar 1, 2024 · Primary completion Dec 1, 2028
Drug: Gardasil 9 Suspension for Injection; Placebo · For: Vulvar HSIL; HPV
Sites: Rotterdam, Netherlands
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use265
- erythema185
- fatigue181
- product use in unapproved indication177
- drug ineffective171
- pain137
- nausea114
- influenza like illness103
- application site erythema102
- headache95
- pruritus88
- pyrexia85
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 2 |
| 2006 | 9 |
| 2007 | 1 |
| 2008 | 7 |
| 2009 | 11 |
| 2010 | 15 |
| 2011 | 55 |
| 2012 | 64 |
| 2013 | 69 |
| 2014 | 64 |
| 2015 | 119 |
| 2016 | 198 |
| 2017 | 220 |
| 2018 | 216 |
| 2019 | 185 |
| 2020 | 211 |
| 2021 | 110 |
| 2022 | 166 |
| 2023 | 163 |
| 2024 | 117 |
| 2025 | 180 |
| 2026 | 148 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zyclara (Imiquimod)
2024 spending
$104K
Beneficiaries
59
81 claims
Per beneficiary
$1,755
$151.05 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $310,475 |
| 2021 | $141,752 |
| 2022 | $97,897 |
| 2023 | $115,077 |
| 2024 | $103,572 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease.
Kibbi N, Owen JL, Worley B, et al. · JAMA Oncol 2022 · Systematic Review, Research Support, N.I.H., Extramural
- Treatment of pediatric alopecia areata: A systematic review.
Barton VR, Toussi A, Awasthi S, et al. · J Am Acad Dermatol 2022 · Systematic Review, Research Support, N.I.H., Extramural
- Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer.
Palefsky JM, Lee JY, Jay N, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Comparative Study
- Treatment of actinic keratosis: a systematic review.
Worley B, Harikumar V, Reynolds K, et al. · Arch Dermatol Res 2023 · Systematic Review
- Guidelines of care for the management of actinic keratosis.
Eisen DB, Asgari MM, Bennett DD, et al. · J Am Acad Dermatol 2021 · Systematic Review
- Topical treatments for cutaneous warts.
Kwok CS, Gibbs S, Bennett C, et al. · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.